

# Schizophrenia - Pipeline Review, H1 2020

<https://marketpublishers.com/r/S24807386E2EN.html>

Date: May 2020

Pages: 383

Price: US\$ 2,000.00 (Single User License)

ID: S24807386E2EN

## Abstracts

Schizophrenia - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia – Pipeline Review, H1 2020, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 1, 13, 15, 24, 3, 56 and 11 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 7 and 1 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of

administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Schizophrenia - Overview

Schizophrenia - Therapeutics Development

Schizophrenia - Therapeutics Assessment

Schizophrenia - Companies Involved in Therapeutics Development

Schizophrenia - Drug Profiles

Schizophrenia - Dormant Projects

Schizophrenia - Discontinued Products

Schizophrenia - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Schizophrenia, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Schizophrenia - Pipeline by AbbVie Inc, H1 2020  
Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc, H1 2020  
Schizophrenia - Pipeline by Adamed Sp zoo, H1 2020  
Schizophrenia - Pipeline by Adare Pharmaceuticals Inc, H1 2020  
Schizophrenia - Pipeline by Adeptio Pharmaceuticals Ltd, H1 2020  
Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc, H1 2020  
Schizophrenia - Pipeline by AgeneBio Inc, H1 2020  
Schizophrenia - Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020  
Schizophrenia - Pipeline by Alkermes Plc, H1 2020  
Schizophrenia - Pipeline by Athersys Inc, H1 2020  
Schizophrenia - Pipeline by Autifony Therapeutics Ltd, H1 2020  
Schizophrenia - Pipeline by Avanir Pharmaceuticals Inc, H1 2020  
Schizophrenia - Pipeline by Avicanna Inc, H1 2020  
Schizophrenia - Pipeline by AviMed Pharmaceuticals LLC, H1 2020  
Schizophrenia - Pipeline by Avineuro Pharmaceuticals Inc, H1 2020  
Schizophrenia - Pipeline by BCWorld Pharm Co Ltd, H1 2020  
Schizophrenia - Dormant Projects, H1 2020  
Schizophrenia - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Schizophrenia, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

AbbVie Inc  
Acadia Pharmaceuticals Inc  
Adamed Sp zoo  
Adare Pharmaceuticals Inc  
Adeptio Pharmaceuticals Ltd  
Aequus Pharmaceuticals Inc  
AgeneBio Inc  
AgoneX Biopharmaceuticals Inc  
Alkermes Plc  
Athersys Inc  
Autifony Therapeutics Ltd  
Avanir Pharmaceuticals Inc  
Avicanna Inc  
AviMed Pharmaceuticals LLC  
Avineuro Pharmaceuticals Inc  
BCWorld Pharm Co Ltd  
Beloteca Inc  
Biogen Inc  
BioStem Technologies Inc  
BioStratum Inc  
BioXcel Therapeutics Inc

Boehringer Ingelheim International GmbH  
Bristol-Myers Squibb Co  
Cadent Therapeutics Inc  
Cerevance Inc  
Cerevel Therapeutics LLC  
Concert Pharmaceuticals Inc  
Curemark LLC  
CuroNZ Ltd  
Daewoong Pharmaceutical Co Ltd  
Daya Drug Discoveries Inc  
Delpor Inc  
Denovo Biopharma LLC  
Echo Pharmaceuticals BV  
Enterin Inc  
F. Hoffmann-La Roche Ltd  
Fabre-Kramer Pharmaceuticals Inc  
Gabather AB  
Genentech Inc  
GlaxoSmithKline Plc  
GP Pharm SA  
GW Pharmaceuticals Plc  
H. Lundbeck AS  
Impel NeuroPharma Inc  
Indivior Plc  
IntelGenx Corp  
Intra-Cellular Therapies Inc  
INVENT Pharmaceuticals Inc  
IRLAB Therapeutics AB  
Jiangsu Nhwa Pharmaceutical Co Ltd  
Johnson & Johnson  
Karuna Therapeutics Inc  
Laboratorios Farmaceuticos Rovi SA  
Lb Pharmaceuticals Inc  
Lead Discovery Center GmbH  
Lohocla Research Corp  
Luye Pharma Group Ltd  
Lyndra Inc  
Mapi Pharma Ltd  
MedinCell SA

Mental-Heal Ltd  
Merck & Co Inc  
Mitsubishi Tanabe Pharma Corp  
Neurocea Pharmaceuticals  
Neurocrine Biosciences Inc  
NeurOp Inc  
NeuroSolis Inc  
Newron Pharmaceuticals SpA  
Omeros Corp  
Otsuka Holdings Co Ltd  
Otsuka Pharmaceutical Co Ltd  
OWP Pharmaceuticals Inc  
Pfizer Inc  
Ra Pharmaceuticals Inc  
Reviva Pharmaceuticals Inc  
Richter Gedeon Nyrt  
Schrodinger LLC  
Sichuan Kelun Pharmaceutical Co Ltd  
Siragen Pharmaceuticals Inc  
SkySea Pharmaceutical Inc  
Sosei Heptares  
Sumitomo Dainippon Pharma Co Ltd  
Sunovion Pharmaceuticals Inc  
SyneuRx International Corp  
Taho Pharmaceuticals Ltd  
Taisho Pharmaceutical Holdings Co Ltd  
Takeda Pharmaceutical Co Ltd  
Terran Biosciences Inc  
Teva Pharmaceutical Industries Ltd  
Vanda Pharmaceuticals Inc  
Vitality Biopharma Inc  
Zysis Ltd



## I would like to order

Product name: Schizophrenia - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/S24807386E2EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S24807386E2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970